Sign in

CIK 0001490978 · Large accelerated filer

Schrodinger, Inc.

Sign in to watch
Ticker
SDGR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
954284541
Phone
503-299-1150
Business address
1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$2,781,663
in 3 filings, $2.8M under 10b5-1 plans

Net −$2,781,663. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-06-18 OBEROI ARUN Director Grant or award +5,997 17,247
2025-06-18 OBEROI ARUN Director Grant or award · Stock Option (right to buy) +9,341 9,341
2025-06-18 Friesner Richard Director Grant or award +5,997 521,697
2025-06-18 Friesner Richard Director Grant or award · Stock Option (right to buy) +9,341 9,341
2025-05-29 Aklian Mannix Vartan See Remarks Grant or award +14,063 14,063
2025-05-29 Aklian Mannix Vartan See Remarks Grant or award · Stock Option (right to buy) +84,375 84,375
2025-05-21 Jain Rachit EVP & CFO Grant or award +9,375 37,097
2025-05-21 Jain Rachit EVP & CFO Grant or award · Stock Option (right to buy) +18,750 18,750
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Option exercise 10b5-1 +13,378 $3.22 $43K 29,003
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Option exercise 10b5-1 +3,345 $2.92 $10K 32,348
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Sale 10b5-1 −8,378 $25.11 $210K 23,970
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Sale 10b5-1 −5,000 $25.11 $126K 18,970
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Sale 10b5-1 −3,345 $25.00 $84K 15,625
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Option exercise · Stock Option (right to buy) 10b5-1 −13,378 0
2025-04-14 Akinsanya Karen President of R&D, Therapeutics Option exercise · Stock Option (right to buy) 10b5-1 −3,345 0
2025-03-07 van Kralingen Bridget A Director Grant or award +10,000 10,000
2025-03-07 van Kralingen Bridget A Director Grant or award · Stock Option (right to buy) +17,050 17,050
2025-03-06 Herman Jenny SVP & Controller Sale 10b5-1 −666 $21.11 $14K 27,349
2025-03-03 Porges Geoffrey Craig EVP & CFO Grant or award +12,500 18,185
2025-03-03 Porges Geoffrey Craig EVP & CFO Grant or award +14,850 33,035

Page 6 of 11 · 214 trades